Pulmonary EmbolismRVD-PENCT07647497
Risk Stratification and Prognostic Value of Right Ventricular Dysfunction Screening Using Transthoracic Echocardiography in Acute Pulmonary Embolism
An observational study of Pulmonary Embolism, run by Sohag University at 2 sites in Egypt.
Trial summary
This observational study evaluates right ventricular dysfunction in patients with acute pulmonary embolism using transthoracic echocardiography and assesses its prognostic significance and risk stratification value. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pulmonary Embolism
- What is being tested?
- Transthoracic Echocardiography
- How many people
- 112 participants
- Where
- 2 sitesEgypt
- Study dates
- 1 Jun 2026to 30 Nov 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients diagnosed as acute pulmonary embolism
Who may be able to join
- Patients aged 18 years and older.
- Patients with a confirmed diagnosis of acute pulmonary embolism.
- Patients who underwent transthoracic echocardiographic assessment for right ventricular dysfunction.
Who cannot join
- Patients younger than 18 years.
- Patients with incomplete clinical data.
- Patients who did not undergo transthoracic echocardiography.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt2 sites, 2 recruiting
- Not yet recruiting
Sohag University hospital
Sohag
Safiya Khalaf Abdallah, Assistant lecturer, 0201090720819, olaamer2026@gmail.com
- Recruiting
Sohag University hospital
Sohag
Safiya Khalaf Abdallah, Assistant lecturer, 0201090720819, olaamer2026@gmail.com
Safiya Khalaf Abdallah, Assistant lecturer
About this study
This observational study evaluates right ventricular dysfunction in patients with acute pulmonary embolism using transthoracic echocardiography and assesses its prognostic significance and risk stratification value.
Read the detailed description
This observational study evaluates right ventricular dysfunction in patients with acute pulmonary embolism using transthoracic echocardiography and assesses its prognostic significance and risk stratification value.
- Conditions
- Pulmonary Embolism
- Being tested
- Transthoracic Echocardiography
- Keywords
- Right Ventricular Dysfunction, Echocardiography, Pulmonary Embolism, Risk Stratification
- Medical subject headings
- Pulmonary Embolism, Ventricular Dysfunction, Right
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Transthoracic EchocardiographyOther
Transthoracic echocardiography performed for assessment of right ventricular dysfunction in patients with acute pulmonary embolism.
| Study group | Role | What they receive |
|---|---|---|
| Patients with acute pulmonary embolism | Patients diagnosed with acute pulmonary embolism who undergo transthoracic echocardiographic assessment for evaluation of right ventricular dysfunction. Receives: Other: Transthoracic Echocardiography |
What is being measured
The primary outcome is the main question the study is designed to answer.
Right ventricular dysfunction as a prognostic marker in acute pulmonary embolism
To assess the prognostic value of right ventricular dysfunction detected by transthoracic echocardiography for risk stratification in patients with acute pulmonary embolism
Measured: From hospital admission until hospital discharge, with an average duration of 7 days.
Secondary outcomes (1)
In-hospital adverse clinical outcomes
To evaluate the occurrence of in-hospital adverse clinical outcomes, including respiratory failure, hemodynamic instability, cardiac arrhythmias, intensive care unit admission, and mortality, and their association with right ventricular dysfunction in patients with acute pulmonary embolism
Measured: From hospital admission until hospital discharge, with an average duration of 7 days.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jun 2026
- Study start1 Jun 2026 (estimated)
- Primary completion30 Nov 2026 (estimated)
- Study completion30 Nov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Pulmonary EmbolismStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 112 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Safia Khalaf Abdallah, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07647497
- Sponsor's protocol ID
- PE-RVD-2026-01...PE.RVD..2026.
- Acronym
- RVD-PE
- Status last verified
- Jun 2026
- First submitted
- 23 May 2026
- Last updated
- 15 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Individual participants data sharing plans are currently undecided
Publications
Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, Huisman MV, Humbert M, Jennings CS, Jimenez D, Kucher N, Lang IM, Lankeit M, Lorusso R, Mazzolai L, Meneveau N, Ni Ainle F, Prandoni P, Pruszczyk P, Righini M, Torbicki A, Van Belle E, Zamorano JL; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020 Jan 21;41(4):543-603. doi: 10.1093/eurheartj/ehz405. No abstract available.
PubMed 31504429
Study at a glance
From the registry record, last updated by the sponsor on 15 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Risk Stratification and Prognostic Value of Right Ventricular Dysfunction Screening Using Transthoracic Echocardiography in Acute Pulmonary Embolism
- ClinicalTrials.gov ID
- NCT07647497
- Acronym / sponsor ID
- RVD-PE / PE-RVD-2026-01...PE.RVD..2026.
- Conditions
- Pulmonary Embolism
- Keywords
- Right Ventricular Dysfunction, Echocardiography, Pulmonary Embolism, Risk Stratification
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 112 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 1 Jun 2026 (estimated)
- Primary completion
- 30 Nov 2026 (estimated)
- Study completion
- 30 Nov 2026 (estimated)
- First posted
- 15 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This observational study evaluates right ventricular dysfunction in patients with acute pulmonary embolism using transthoracic echocardiography and assesses its prognostic significance and risk stratification value.
Detailed description
This observational study evaluates right ventricular dysfunction in patients with acute pulmonary embolism using transthoracic echocardiography and assesses its prognostic significance and risk stratification value.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with acute pulmonary embolism | – | Other: Transthoracic EchocardiographyPatients diagnosed with acute pulmonary embolism who undergo transthoracic echocardiographic assessment for evaluation of right ventricular dysfunction. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients diagnosed as acute pulmonary embolism
Key inclusion criteria (3 listed)
- Patients aged 18 years and older.
- Patients with a confirmed diagnosis of acute pulmonary embolism.
- Patients who underwent transthoracic echocardiographic assessment for right ventricular dysfunction.
Key exclusion criteria (3 listed)
- Patients younger than 18 years.
- Patients with incomplete clinical data.
- Patients who did not undergo transthoracic echocardiography.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Transthoracic EchocardiographyTransthoracic echocardiography performed for assessment of right ventricular dysfunction in patients with acute pulmonary embolism. | Other | Patients with acute pulmonary embolism |
Primary outcome
Right ventricular dysfunction as a prognostic marker in acute pulmonary embolism
Time frame: From hospital admission until hospital discharge, with an average duration of 7 days.
To assess the prognostic value of right ventricular dysfunction detected by transthoracic echocardiography for risk stratification in patients with acute pulmonary embolism
1 secondary outcome
In-hospital adverse clinical outcomes
Time frame: From hospital admission until hospital discharge, with an average duration of 7 days.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jun 2026.
- Background: PubMed 31504429Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, Huisman MV, Humbert M, Jennings CS, Jimenez D, Kucher N, Lang IM, Lankeit M, Lorusso R, Mazzolai L, Meneveau N, Ni Ainle F, Prandoni P, Pruszczyk P, Righini M, Torbicki A, Van Belle E, Zamorano JL; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020 Jan 21;41(4):543-603. doi: 10.1093/eurheartj/ehz405. No abstract available.
- Individual participant dataSharing planned: Undecided. Individual participants data sharing plans are currently undecided
Related trials for Pulmonary Embolism
Active, not recruitingPhase 3
Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy
Pulmonary Embolism
Not yet recruitingPhase 4
Reduced-Dose Versus Full-Dose Alteplase for High-Risk Pulmonary Embolism
Pulmonary Embolism Acute
Not yet recruiting
Large Language Model Support for CTEPH Differential Diagnosis
Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Acute Pulmonary Embolism (PE)
RecruitingObservational study
A Real-World Study of EkoSonic Endovascular System in Chinese Populations With Acute Pulmonary Embolism
Acute Pulmonary Embolism
Not yet recruiting
Exclusion of Left Atrial Appendage Thrombus in Emergency Department Patients With Atrial Fibrillation Undergoing CT to Assess for Pulmonary Embolus: A Feasibility Study
Atrial Fibrillation (AF), Pulmonary Embolism (PE)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pulmonary Embolism, run by Sohag University at 2 sites in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Safiya Khalaf Abdallah, Assistant lecturer (0201090720819, olaamer2026@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Right ventricular dysfunction as a prognostic marker in acute pulmonary embolism (time frame: From hospital admission until hospital discharge, with an average duration of 7 days.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07647497, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jun 2026; AzTrials last refreshed its copy on 29 Oct 2026.